Oncopeptides AB (publ) (STO:ONCO)
Sweden · Delayed Price · Currency is SEK 1.770
+0.041 (2.37%)
Jun 12, 2026, 5:29 PM CET
Oncopeptides AB Cash Flow Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -221.1 | -249.59 | -284.61 | -249.11 | -337.95 | -1,430 |
Depreciation & Amortization | 9.67 | 9.67 | 9.75 | 11.04 | 16.84 | 14.57 |
Other Amortization | - | - | - | - | 0.32 | 0.42 |
Asset Writedown & Restructuring Costs | - | - | - | - | - | 16.59 |
Stock-Based Compensation | 2.72 | 2.72 | 10.91 | 11.5 | 14.81 | 14.54 |
Other Operating Activities | 23.98 | 20.13 | 6.06 | 4.14 | -3.84 | -94.11 |
Change in Accounts Receivable | 8.54 | 8.54 | -4.3 | -16.02 | 53.17 | 24.66 |
Change in Inventory | -3.87 | -3.87 | -1.95 | -2.42 | -1.46 | -0.32 |
Change in Accounts Payable | -17.47 | -17.47 | 3.15 | -13.19 | -22.89 | -104.91 |
Change in Other Net Operating Assets | -2.62 | 6.99 | 0.42 | -25.42 | -139.52 | 42.49 |
Operating Cash Flow | -200.16 | -222.88 | -260.57 | -279.49 | -420.51 | -1,516 |
Capital Expenditures | - | - | -0.36 | -0.12 | -2.51 | -0.34 |
Investment in Securities | - | - | 0.85 | -0 | - | - |
Other Investing Activities | - | - | 0 | 0 | - | - |
Investing Cash Flow | - | - | 0.5 | -0.12 | -2.51 | -0.34 |
Long-Term Debt Repaid | - | -8.16 | -8.03 | -9.14 | -15.54 | -15.41 |
Net Debt Issued (Repaid) | -8.16 | -8.16 | -8.03 | -9.14 | -15.54 | -15.41 |
Issuance of Common Stock | 151.41 | 151.41 | 313.48 | 116.02 | 436.02 | 1,116 |
Other Financing Activities | 157.51 | -14.7 | -41.64 | - | -28.07 | -67.05 |
Financing Cash Flow | 300.76 | 128.55 | 263.81 | 106.89 | 392.4 | 1,034 |
Foreign Exchange Rate Adjustments | -2.67 | -1.95 | 1.39 | 1.61 | 12.94 | 4.63 |
Miscellaneous Cash Flow Adjustments | - | - | - | -0 | - | -0 |
Net Cash Flow | 97.93 | -96.28 | 5.13 | -171.11 | -17.67 | -478.07 |
Free Cash Flow | -200.16 | -222.88 | -260.93 | -279.61 | -423.02 | -1,517 |
Free Cash Flow Margin | -240.47% | -313.40% | -824.47% | -793.89% | -5063.03% | -1282.16% |
Free Cash Flow Per Share | - | -0.98 | -1.57 | -3.09 | -5.14 | -20.14 |
Cash Interest Paid | 2.8 | 2.8 | 0 | 0.57 | 0.88 | 0.95 |
Cash Income Tax Paid | 0.11 | 0.11 | -0.59 | -1.65 | 0.04 | 12.22 |
Levered Free Cash Flow | -120.6 | -138.49 | -169.03 | -191.36 | -289.31 | -1,086 |
Unlevered Free Cash Flow | -111.57 | -129.46 | -161.12 | -187.74 | -288.76 | -1,086 |
Change in Working Capital | -15.42 | -5.82 | -2.68 | -57.06 | -110.69 | -38.08 |